Sera prognostics chief data officer Paul Kearney sells $24,466 in stock

SALT LAKE CITY—Paul Kearney, the Chief Data Officer at Sera Prognostics , Inc. (NASDAQ:SERA), recently sold shares in the company, according to a regulatory filing. The company, currently valued at $137 million, has seen its stock decline nearly 48% year-to-date, with shares trading near their 52-week low of $3.84. On February 12, Kearney sold 5,342 shares of Class A Common Stock, amounting to a total transaction value of $24,466. The shares were sold at a weighted average price of $4.58, with the sale conducted as part of a block trade at prices ranging from $4.14 to $5.09. According to InvestingPro data, the stock's technical indicators suggest oversold conditions, while the company maintains a healthy balance sheet with more cash than debt.

The transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the company's policy. This sale is not considered a discretionary transaction by Kearney. Following the transaction, Kearney holds 158,128 shares in the company. For deeper insights into insider trading patterns and comprehensive analysis, including 10+ additional ProTips, check out the detailed Pro Research Report available on InvestingPro.

In other recent news, Sera Prognostics, a medical laboratory services provider, has halted its $50 million stock offering. The company's decision to cease the current ATM offering provides a pause in their capital-raising activities, requiring a new prospectus supplement for any future equity sales. The sales agreement with TD Cowen, however, remains effective, and Sera Prognostics has reserved the right to initiate a new offering after filing a new prospectus or prospectus supplement.

In a separate development, Sera Prognostics has initiated a public offering of its Class A common stock and pre-funded warrants. The offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets, and is contingent on market conditions. The proceeds are aimed at expanding U.S. commercial operations, EU growth preparations, FDA approval efforts for its PreTRM test, and other corporate purposes.

In other recent developments, Sera Prognostics disclosed that the Society for Maternal Fetal Medicine (SMFM) has published an abstract with topline results from the PRIME study. The study's findings, focusing on improving neonatal outcomes through prematurity risk assessment combined with clinical interventions, are set to be presented in detail later this month. Following the presentation, Sera Prognostics plans to host a conference call and live audio webcast for a more in-depth discussion of the PRIME study's outcomes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.